Clinical Trial Diversity: FDA Rejects Calls For Enrollment Mandates
Executive Summary
Requiring that underrepresented populations be enrolled based upon disease prevalence is only way to ensure adequate diversity, some stakeholders say; agency continues to prefer more flexible approach offered by guidance, and PhRMA says mandates would lengthen development timelines for new drugs.